Hydatid Disease (Echinococcosis)

1. Clinical Overview

Summary

Hydatid disease (echinococcosis) is a zoonotic parasitic infection caused by the larval stage of tapeworms belonging to the genus Echinococcus. The two principal forms are cystic echinococcosis (CE) caused by Echinococcus granulosus and alveolar echinococcosis (AE) caused by E. multilocularis. CE is the most common form worldwide, endemic in sheep-rearing regions of the Mediterranean, Middle East, South America, Central Asia, Australia, and East Africa. [1,2]

Humans are accidental intermediate hosts, infected through ingestion of parasite eggs from contaminated food or contact with definitive hosts (primarily dogs). The larvae migrate to the liver (60-70%) or lungs (20-30%), forming slowly expanding fluid-filled cysts that may remain asymptomatic for years. [3] Clinical presentation depends on cyst location, size, and complications including rupture (with risk of life-threatening anaphylaxis), secondary infection, or mass effect. [4]

Diagnosis relies on characteristic imaging (ultrasound/CT showing daughter cysts, hydatid sand) combined with serological testing. The WHO Informal Working Group on Echinococcosis (WHO-IWGE) ultrasound classification (CE1-CE5) guides management, which ranges from watch-and-wait for inactive cysts to medical therapy (albendazole), percutaneous treatment (PAIR), or surgery depending on cyst stage and complications. [5,6]

Key Facts

• Causative Organisms:

  • Echinococcus granulosus (cystic echinococcosis - most common)
  • E. multilocularis (alveolar echinococcosis - more aggressive)
  • E. vogeli and E. oligarthrus (polycystic echinococcosis - rare)

• Life Cycle: Dog (definitive host) → Egg in faeces → Sheep/cattle/human (intermediate hosts) → Larval cyst development → Dog ingests infected viscera (cycle complete)

• Human Infection: Accidental intermediate host (dead-end); infected via faecal-oral route

• Anatomical Sites:

  • "Liver: 60-70%"
  • "Lungs: 20-30%"
  • "Other: Spleen, kidney, bone, brain, heart (less than 10%)"

• Key Danger: Cyst rupture → Anaphylactic shock + Dissemination

• Diagnosis: Imaging (daughter cysts, "spoke-wheel" appearance) + Serology (IgG ELISA)

• Treatment Options: Watch-and-wait, albendazole, PAIR procedure, surgical excision

• Global Burden: Estimated 1 million cases worldwide; significant disability-adjusted life years (DALYs) in endemic regions [2]

Clinical Pearls

"Dog-Sheep-Human Triangle": The classic CE transmission cycle. Dogs (definitive host) harbour adult tapeworms in their intestines. Eggs passed in dog faeces contaminate pastures where sheep (intermediate hosts) graze. Humans become accidental intermediate hosts through contact with infected dogs or contaminated vegetables/water.

"Daughter Cysts = Diagnostic": The presence of smaller "daughter cysts" within a larger parent cyst on imaging is pathognomonic for hydatid disease. This finding distinguishes hydatid cysts from simple hepatic cysts or other cystic lesions. [6]

"Rupture = Anaphylaxis": Cyst fluid contains highly antigenic parasitic proteins. Spontaneous or traumatic rupture, or surgical spillage, can cause immediate IgE-mediated anaphylaxis with cardiovascular collapse. Anaphylaxis preparedness is mandatory during PAIR or surgery. [4]

"Albendazole Before Any Intervention": Pre-treatment with albendazole (typically 4 days before PAIR or surgery) reduces cyst viability and decreases the risk of secondary echinococcosis if cyst contents spill. Continue for 1-3 months post-procedure. [7]

"WHO CE Classification Guides Management":

• CE1-CE2 (active): Consider PAIR or surgery + albendazole
• CE3 (transitional): Usually PAIR + albendazole
• CE4-CE5 (inactive/calcified): Watch-and-wait; medical treatment ineffective [5]

"Eosinophilia is Inconsistent": Unlike many helminthic infections, peripheral eosinophilia is present in only 20-40% of cases and is more common after cyst leakage or rupture.

---

2. Epidemiology

Global Distribution

Cystic echinococcosis is endemic in regions where pastoral livestock farming is practiced, particularly in areas with close human-dog-livestock contact and inadequate sanitary infrastructure. [2]

High Endemicity Regions:

• Mediterranean basin (southern Europe, North Africa)
• Middle East (Turkey, Iran, Iraq)
• Central and South America (Argentina, Uruguay, Peru, Chile)
• Central Asia (Kazakhstan, Uzbekistan, western China)
• East Africa (Kenya, Ethiopia)
• Australia (rural areas)

Alveolar echinococcosis (E. multilocularis) is primarily found in the Northern Hemisphere: Alaska, Canada, central and eastern Europe, Russia, and parts of China and Japan. [8]

Incidence and Prevalence

Global Burden: The WHO estimates over 1 million people are affected by CE at any one time, with surgical treatment costs exceeding $193 million annually in endemic countries. [2]

Age and Gender

• Age: Peak diagnosis typically 20-50 years, reflecting the long latency period (often 5-20 years from infection to symptom onset)
• Gender: Slight male predominance (1.2-1.5:1) in most series, likely reflecting occupational exposure [1]
• Children: Paediatric cases occur in highly endemic areas; shorter incubation suggests higher parasite load exposure

Risk Factors

---

3. Aetiology and Pathophysiology

The Parasite

Cystic Echinococcosis (CE): Caused by the Echinococcus granulosus species complex (formerly considered a single species, now recognized as multiple genotypes G1-G10 with different host preferences and geographical distributions). [9]

Alveolar Echinococcosis (AE): Caused by E. multilocularis, a more aggressive form with infiltrative tumour-like growth, primarily affecting foxes as definitive hosts.

Life Cycle

Exam Detail: 1. Definitive Host (Carnivore - Dog/Fox)

• Adult tapeworm lives in small intestine (2-7mm length, consisting of 3-4 segments)
• Terminal gravid proglottid contains ~500-800 eggs
• Eggs released in faeces into environment

2. Egg Stage

• Eggs highly resistant: survive for months in moist, cool conditions
• Infective immediately upon release
• Contain oncosphere (hexacanth embryo) with six hooklets

3. Intermediate Host (Sheep/Cattle/Human)

• Accidental ingestion of eggs (contaminated food, water, dog contact)
• Eggs hatch in duodenum → Oncosphere released
• Oncosphere penetrates intestinal mucosa → Enters portal circulation
• Larvae typically lodge in liver (first capillary bed) or lungs (if bypass liver)

4. Larval Cyst Development

• Oncosphere develops into fluid-filled hydatid cyst over months-years
• Cyst structure (from inner to outer):
  • "Germinal layer (inner cellular layer): Produces protoscoleces and daughter cysts"
  • "Laminated layer (acellular): Protective layer, resistant to host immune response"
  • "Pericyst (host-derived): Fibrous adventitial layer formed by host inflammatory reaction"

5. Cyst Contents

• Hydatid fluid: Clear, antigenic, rich in parasite proteins
• Protoscoleces: Inverted larval tapeworm heads (appear as "hydatid sand" on imaging when sediment)
• Daughter cysts: Smaller cysts within parent cyst (characteristic feature)
• Brood capsules: Contain clusters of protoscoleces

6. Cycle Completion

• Definitive host (dog) consumes infected viscera containing protoscoleces
• Protoscoleces evaginate and attach to intestinal mucosa
• Develop into adult tapeworms in 6-8 weeks
• Cycle continues

Human Infection: Humans are accidental dead-end hosts. Cysts do not mature to adult worms, and humans do not transmit infection.

Molecular and Immunological Pathophysiology

Host Immune Response:

• Initial infection triggers Th2-type immune response (eosinophilia, IgE production)
• Laminated layer protects parasite from immune attack (acellular, non-antigenic)
• Pericyst formation represents chronic granulomatous inflammation
• Humoral immunity (IgG, IgE) develops but does not clear infection
• Cell-mediated immunity suppressed by parasite immune evasion mechanisms [10]

Cyst Growth:

• Gradual expansion at ~1-5 cm per year (variable)
• Growth rate depends on host immune response, cyst location, parasite genotype
• Liver cysts may reach > 20 cm diameter
• Cyst pressure can cause atrophy of surrounding parenchyma

Cyst Evolution: Following WHO-IWGE classification, cysts evolve through active, transitional, and inactive stages:

• Active (CE1, CE2): Viable germinal layer producing protoscoleces
• Transitional (CE3): Detachment of membranes, reduced viability
• Inactive (CE4, CE5): Cyst death, solidification, calcification [5]

Why Rupture Causes Anaphylaxis:

• Hydatid fluid contains excretory-secretory antigens (antigen 5, antigen B)
• Chronic low-level leakage sensitizes host (IgE production)
• Acute rupture → Massive antigen exposure → Mast cell degranulation → Anaphylaxis
• Estimated risk of anaphylaxis with rupture: 10-25% [4]

---

4. Clinical Presentation

General Principles

• Asymptomatic Phase: May last years to decades; many cysts discovered incidentally on imaging for unrelated reasons
• Symptomatic Phase: Occurs when cysts cause mass effect, rupture, or secondary complications
• Symptoms Non-Specific: Often mimic other space-occupying lesions

Hepatic Cystic Echinococcosis (60-70%)

Asymptomatic/Incidental:

• Most common presentation in endemic screening programs
• Detected on abdominal ultrasound for other indications

Mass Effect Symptoms:

• Right upper quadrant pain or discomfort (dull, dragging sensation)
• Palpable mass (hepatomegaly)
• Early satiety, nausea (gastric compression)
• Fever (if secondary bacterial infection)

Biliary Complications (10-15% of hepatic cysts): [11]

• Jaundice (obstruction by extrinsic compression or intrabiliary rupture)
• Cholangitis (fever, rigors, RUQ pain)
• Acute cholecystitis (cystic duct obstruction)
• Pancreatitis (if cyst ruptures into pancreatic duct)

Signs on Examination:

• Hepatomegaly (smooth or nodular)
• Palpable cystic mass (RUQ)
• Jaundice (if biliary obstruction)
• Fever (secondary infection)

Pulmonary Cystic Echinococcosis (20-30%)

Asymptomatic: Common, especially for small peripheral cysts

Symptomatic:

• Chronic cough (most common symptom)
• Chest pain (dull, pleuritic if pleural involvement)
• Dyspnoea (large cysts compressing lung parenchyma)
• Haemoptysis (erosion into bronchus)

Cyst Rupture into Bronchus (10-20% of pulmonary cases):

• Sudden onset of cough with copious watery sputum
• Expectoration of cyst contents: "Grape-skin" membranes or "salty" taste described
• Hydatid vomique: Expectoration of daughter cysts and membranes (pathognomonic but rare)
• May be complicated by bacterial superinfection (lung abscess)

Signs on Examination:

• Dullness to percussion
• Reduced breath sounds over cyst
• Bronchial breathing (if compressed/consolidated adjacent lung)

Other Sites (Rare, less than 10% Combined)

Cyst Rupture and Anaphylaxis

Types of Rupture:

1. Contained Rupture: Leak into pericyst (minimal symptoms, may sensitize host)
2. Communicating Rupture: Into biliary tree, bronchus, or adjacent hollow viscus (local symptoms)
3. Free Rupture: Into peritoneal cavity, pleural cavity, pericardium (medical emergency)

Anaphylactic Reaction: [4]

• Sudden onset (minutes to hours after rupture)
• Urticaria, pruritus, angioedema
• Bronchospasm, wheezing
• Hypotension, cardiovascular collapse
• Can be fatal without immediate resuscitation

Secondary Echinococcosis:

• Spillage of protoscoleces → Seeding of new cysts
• Multiple daughter cysts throughout peritoneal or pleural cavity
• Difficult to treat; requires prolonged albendazole and potentially multiple surgeries

---

5. Clinical Examination

Hepatic Hydatid Cyst

Inspection:

• Visible distension (RUQ/epigastrium) in large cysts
• Jaundice (biliary obstruction)
• Cachexia (chronic infection, malnutrition in endemic settings)

Palpation:

• Hepatomegaly (smooth or irregular edge)
• Palpable cystic mass (RUQ): Firm, non-tender (unless infected), non-pulsatile
• Hydatid fremitus: Palpable thrill on coughing (rare, classical sign, seldom elicited)
• Tenderness if secondary infection or rupture

Percussion:

• Dullness over liver/mass
• Loss of normal liver dullness transition may suggest enlargement

Auscultation:

• Usually unremarkable
• Friction rub (if pericyst inflammation involves capsule)

Pulmonary Hydatid Cyst

Inspection:

• Tachypnoea (large cyst, infection)
• Reduced chest expansion (affected side)

Palpation:

• Reduced chest expansion
• Reduced tactile vocal fremitus

Percussion:

• Dullness over cyst (fluid-filled)
• "Cracked-pot" resonance described historically (air-fluid level after partial rupture) - rare

Auscultation:

• Reduced breath sounds over cyst
• Bronchial breathing (compressed adjacent lung)
• Crepitations (secondary infection, rupture)

Spleen, Kidney, Other Sites

• Splenomegaly (palpable spleen)
• Flank mass (renal cyst)
• Neurological signs (brain cyst): Focal deficits, papilloedema
• Pathological fracture deformity (bone involvement)

---

6. Differential Diagnosis

Hepatic Cysts

Pulmonary Cysts/Masses

---

7. Investigations

Imaging

Ultrasound (First-Line for Hepatic/Splenic Cysts) [6]

Advantages:

• Non-invasive, no radiation, widely available in endemic areas
• Real-time assessment
• Can detect daughter cysts, hydatid sand, membrane detachment

WHO-IWGE Ultrasound Classification: [5]

Key Findings:

• Daughter cysts: Virtually pathognomonic
• Hydatid sand: Echogenic sediment (protoscoleces) shifting with patient position
• Double-line sign: Separation of germinal and laminated layers
• Water-lily sign: Floating membranes after partial collapse

Computed Tomography (CT)

Indications:

• Surgical planning (defines anatomical relationships)
• Detection of complications (biliary communication, rupture)
• Pulmonary cysts (better than ultrasound)
• Detection of calcification (better than ultrasound)

Findings:

• Well-defined, low-attenuation cystic lesion
• Daughter cysts (low attenuation lesions within parent cyst)
• Calcification (rim or complete) in CE4/CE5
• "Spoke-wheel" appearance in some cases

Magnetic Resonance Imaging (MRI)

Indications:

• Assessment of biliary tree involvement (MRCP)
• Suspected vascular involvement
• Spinal/CNS hydatid cysts
• Pregnancy (avoid CT radiation)

Findings:

• T1: Low signal (fluid)
• T2: High signal (fluid), low signal rim (pericyst)
• Daughter cysts clearly delineated

Chest X-Ray (Pulmonary Cysts)

Findings:

• Well-defined round/oval mass
• "Water-lily sign" (floating membranes if ruptured into bronchus)
• Air-fluid level (partial rupture)
• Meniscus sign (air between cyst and pericyst)

Serology

Echinococcal IgG Antibody Testing:

Limitations:

• False negatives: Intact cysts (no antigen leak), lung/bone cysts, immunocompromised patients
• False positives: Cross-reactivity with other cestode infections (e.g., Taenia, Schistosoma)
• Serology may remain positive for years after successful treatment

Antigen Detection:

• Detection of circulating echinococcal antigens (e.g., antigen Em2, antigen 5) under investigation
• Higher specificity but not yet widely available

Laboratory Tests

Full Blood Count:

• Eosinophilia: Present in only 20-40% of cases; more common with cyst rupture or leak
• Leukocytosis (secondary bacterial infection)

Liver Function Tests (hepatic cysts):

• Usually normal unless biliary obstruction
• Elevated ALP, GGT, bilirubin (biliary communication/obstruction)
• Transaminitis (secondary bacterial infection, large cysts)

Renal Function (renal cysts):

• May show impaired function if obstruction or parenchymal destruction

Cyst Aspiration (Rarely Performed)

Indications:

• Diagnostic uncertainty (in combination with imaging and serology)
• PAIR procedure (therapeutic and diagnostic)

Findings:

• Protoscoleces ("hydatid sand") on microscopy - diagnostic
• Hooklets visible
• Clear fluid

Contraindications to Diagnostic Aspiration Alone:

• High risk of anaphylaxis (requires resuscitation facilities)
• Risk of spillage and secondary echinococcosis
• Should NOT be performed without albendazole pre-treatment and full PAIR protocol

---

8. Management

General Principles

Management strategy depends on:

1. Cyst stage (WHO-IWGE classification)
2. Cyst size and location
3. Presence of complications
4. Patient symptoms and comorbidities
5. Local expertise and resources

Four main management options: [7,12]

• Watch-and-wait (inactive cysts)
• Medical therapy (albendazole)
• Percutaneous treatment (PAIR)
• Surgery

1. Medical Therapy

Albendazole

Mechanism: Benzimidazole that inhibits parasite microtubule formation → protoscoleces death

Indications:

• Inoperable cysts (multiple, unfavourable location)
• Small cysts (less than 5 cm, CE1)
• Adjunct to PAIR or surgery (pre- and post-treatment)
• Peritoneal/disseminated echinococcosis
• Paediatric cases (if surgery avoided)

Dosing:

• Standard: 10-15 mg/kg/day in two divided doses (max 800 mg/day)
• Typical adult dose: 400 mg twice daily
• Duration:
  • "Monotherapy: 3-6 months (repeated cycles with 2-week breaks)"
  • "Pre-PAIR: 4 days before procedure"
  • "Post-PAIR/Surgery: 1-3 months"

Monitoring:

• Baseline: FBC, LFTs
• During treatment: LFTs every 2 weeks for first month, then monthly
• Discontinue if ALT > 3× upper limit of normal

Efficacy:

• Cure rate (cyst disappearance): 30-40% with prolonged treatment [13]
• Cyst regression/inactivation: 50-70%
• Less effective for larger cysts (> 10 cm), CE2/CE3 stage
• Pulmonary cysts respond less well than hepatic cysts

Adverse Effects:

• Hepatotoxicity (transaminitis, 10-20%; severe less than 5%)
• Bone marrow suppression (rare)
• Alopecia (transient)
• Gastrointestinal upset
• Teratogenic (contraindicated in pregnancy)

Mebendazole

• Alternative to albendazole but less well absorbed
• Higher doses required (40-50 mg/kg/day)
• Less commonly used

2. PAIR (Puncture-Aspiration-Injection-Reaspiration) [7,14]

Indications (WHO-IWGE criteria):

• CE1 and CE3a cysts
• Cysts > 5 cm diameter
• Accessible cysts (not adjacent to major vessels/bile ducts)
• Patients unfit for surgery

Contraindications:

• Inaccessible cysts (deep, risky trajectory)
• Inactive cysts (CE4, CE5)
• Superficial cysts (high rupture risk)
• Cysts with biliary communication
• Pregnancy

Procedure:

1. Pre-treatment: Albendazole 400 mg BD for 4 days before
2. Procedure:
   • Ultrasound-guided needle insertion (usually 18-20G)
   • Aspiration of cyst fluid (send for microscopy, culture)
   • Injection of scolicidal agent (hypertonic saline 20% or 95% ethanol, ~30% cyst volume)
   • Leave scolicidal agent for 15-20 minutes
   • Reaspiration of fluid
3. Post-procedure: Albendazole 400 mg BD for 1-3 months

Scolicidal Agents:

• Hypertonic saline (20%): Most common, effective, low toxicity
• 95% ethanol: Effective but risk of sclerosing cholangitis if biliary communication
• Cetrimide: Less commonly used

Monitoring During Procedure:

• Anaphylaxis preparedness: Resuscitation equipment, adrenaline ready
• Ultrasound guidance throughout

Efficacy:

• Cure rate: 70-90% (cyst complete resolution or solidification) [14]
• Lower recurrence than surgery in selected cases (2-5%)

Complications:

• Anaphylaxis (1-2%)
• Secondary echinococcosis (spillage, less than 1% with proper technique)
• Infection (rare)
• Biliary communication (if pre-existing communication not detected)

3. Surgery

Indications:

• Large cysts (> 10 cm)
• Complicated cysts: Biliary rupture, infection, extrinsic compression
• CE2 and CE3b cysts (multiple daughter cysts)
• Superficial cysts at high rupture risk
• Failed medical therapy or PAIR
• Pulmonary cysts (especially with bronchial communication)

Pre-operative Management:

• Albendazole 400 mg BD for 4-7 days pre-operatively
• Anaphylaxis preparedness in theatre
• Avoid cyst puncture/rupture during induction/intubation (external compression)

Surgical Options:

Conservative Surgery (Cyst-Preserving):

1. Unroofing + Drainage:

   • Open cyst, evacuate contents, leave pericyst in situ
   • +/- Omentoplasty to obliterate cavity
   • Risk: Biliary leak, infection, recurrence (5-10%)

2. Cystectomy:

   • Excision of cyst (endo-cyst and laminated membrane) with preservation of pericyst
   • Lower recurrence than unroofing

Radical Surgery (Cyst-Removing):

1. Pericystectomy:

   • Complete excision including pericyst
   • Lowest recurrence (less than 2%) but higher morbidity

2. Liver Resection (Segmentectomy/Lobectomy):

   • For large cysts with destroyed liver parenchyma
   • For cysts with biliary fistula unmanageable by conservative means

Intra-operative Measures:

• Isolation of operative field: Packs soaked in scolicidal agent around cyst
• Scolicidal injection into cyst (hypertonic saline 20%) for 5-10 minutes before opening
• Aspiration before opening: Reduce intra-cystic pressure
• Inspect for biliary communication: Bile in cyst fluid, methylene blue test
• Biliary fistula management: Suture closure, biliary drainage if needed
• Cavity management: Omentoplasty, capitonnage (obliterate residual cavity)

Post-operative:

• Albendazole 400 mg BD for 1-3 months
• Monitor for bile leak, infection, recurrence

Pulmonary Hydatid Cyst Surgery:

• Cystotomy: Open cyst, remove contents, capitonnage (closure of cavity)
• Lobectomy: For destroyed lung or extensive disease
• Bronchial fistula closure if present

Efficacy:

• Cure rate: 85-95%
• Recurrence: 2-10% (depends on technique, spillage)

Complications:

• Anaphylaxis (1-5%)
• Spillage → Secondary echinococcosis
• Biliary leak (10-15% with biliary communication)
• Infection
• Recurrence

4. Watch-and-Wait

Indications:

• Inactive cysts (CE4, CE5)
• Small asymptomatic cysts (CE1 less than 5 cm) in elderly/high surgical risk patients
• Patients refusing intervention

Monitoring:

• Ultrasound every 6-12 months for 2 years, then annually
• Serology (declining titres suggest inactivation)
• Educate patient on rupture symptoms (seek immediate care)

Management Algorithm

┌──────────────────────────────────────────────────────────────┐
│   HYDATID DISEASE (CYSTIC ECHINOCOCCOSIS) MANAGEMENT         │
├──────────────────────────────────────────────────────────────┤
│                                                              │
│  STEP 1: CONFIRM DIAGNOSIS                                   │
│  • Imaging (US/CT) + Serology                                │
│  • WHO-IWGE Classification (CE1-CE5)                         │
│                                                              │
│  STEP 2: ASSESS CYST STAGE                                   │
│                                                              │
│  ┌─────────────────────────────────────────────────────┐    │
│  │ CE1 (Unilocular, simple)                            │    │
│  │  → less than 5
cm: Albendazole alone OR watch-and-wait       │    │
│  │  → > 5
cm: PAIR + albendazole OR surgery             │    │
│  └─────────────────────────────────────────────────────┘    │
│                                                              │
│  ┌─────────────────────────────────────────────────────┐    │
│  │ CE2 (Multivesicular, daughter cysts)                │    │
│  │  → Surgery + albendazole (preferred)                │    │
│  │  → PAIR + albendazole (if operable risk high)      │    │
│  └─────────────────────────────────────────────────────┘    │
│                                                              │
│  ┌─────────────────────────────────────────────────────┐    │
│  │ CE3a (Detached membrane)                            │    │
│  │  → PAIR + albendazole                               │    │
│  └─────────────────────────────────────────────────────┘    │
│                                                              │
│  ┌─────────────────────────────────────────────────────┐    │
│  │ CE3b (Predominantly solid)                          │    │
│  │  → Surgery + albendazole                            │    │
│  └─────────────────────────────────────────────────────┘    │
│                                                              │
│  ┌─────────────────────────────────────────────────────┐    │
│  │ CE4 / CE5 (Inactive, calcified)                     │    │
│  │  → Watch-and-wait (6-12 monthly US)                 │    │
│  │  → No medical treatment indicated                   │    │
│  └─────────────────────────────────────────────────────┘    │
│                                                              │
│  STEP 3: ASSESS COMPLICATIONS                                │
│  • Biliary rupture → Surgery                                │
│  • Secondary infection → Antibiotics + drainage/surgery     │
│  • Rupture/anaphylaxis → Emergency resuscitation            │
│                                                              │
│  ⚠️ ALBENDAZOLE PRE-TREATMENT ESSENTIAL for PAIR/surgery    │
│  ⚠️ ANAPHYLAXIS KIT ready for all interventions             │
│                                                              │
└──────────────────────────────────────────────────────────────┘

Management of Complications

Anaphylaxis (Cyst Rupture)

Emergency Management:

1. Immediate: Adrenaline 0.5 mg IM (1:1000), repeat every 5 minutes if needed
2. IV access: Aggressive fluid resuscitation (crystalloid)
3. Airway: High-flow oxygen, consider intubation if severe bronchospasm/angioedema
4. Adjuncts:
   • Antihistamines (chlorphenamine 10 mg IV)
   • Corticosteroids (hydrocortisone 200 mg IV)
   • Bronchodilators (salbutamol nebulized)
5. Secondary echinococcosis prophylaxis: Start albendazole 400 mg BD immediately if rupture confirmed

Biliary Rupture/Fistula

Presentation: Jaundice, cholangitis, biliary colic

Investigations: MRCP or ERCP

Management:

• ERCP with sphincterotomy + extraction of cyst material if accessible
• Surgery if ERCP fails: Cystectomy + biliary fistula repair + T-tube drainage
• Albendazole peri-operatively

Secondary Bacterial Infection

Presentation: Fever, leukocytosis, RUQ pain

Investigations: Blood cultures, cyst aspiration if accessible

Management:

• Broad-spectrum antibiotics (e.g., piperacillin-tazobactam)
• Drainage (percutaneous or surgical)
• +/- Albendazole (opinions vary; may not penetrate infected cyst well)

---

9. Complications

Of the Disease

Of Treatment

---

10. Prognosis and Outcomes

Natural History (Untreated)

• Asymptomatic cysts: May remain stable for years; slow growth (~1-5 cm/year)
• Spontaneous involution: Rare; some cysts may degenerate and calcify (CE4/CE5)
• Progression to symptomatic disease: Depends on size, location, growth rate
• Mortality (untreated symptomatic cysts): 2-4% per year (primarily from rupture complications) [2]

With Treatment

Medical Therapy (Albendazole):

• Complete cure (cyst disappearance): 30-40%
• Cyst regression/inactivation: 50-70%
• Relapse after stopping treatment: 10-20% [13]
• Better outcomes for smaller cysts, CE1 stage

PAIR:

• Cure rate: 70-90% (cyst solidification/resolution)
• Recurrence: 2-5%
• Mortality: less than 0.5%
• Shorter hospital stay and recovery than surgery [14]

Surgery:

• Cure rate: 85-95%
• Recurrence: 2-10% (depends on technique, spillage, adjuvant albendazole)
• Mortality: 1-3% (depends on patient comorbidities, surgical complexity)
• Morbidity: 10-25% (bile leak, infection, wound complications) [12]

Long-Term Follow-Up

Recommended:

• Imaging (ultrasound) at 6, 12, 24 months post-treatment, then annually for 5 years
• Serology: Declining antibody titres suggest cure (may take years to become negative)
• Persistent high titres or rising titres → Suspect recurrence or residual disease

Recurrence Risk Factors:

• Incomplete cyst excision
• Cyst spillage during procedure
• Inadequate albendazole treatment
• Multiple cysts
• Peritoneal seeding

Quality of Life

• Pre-treatment: Reduced if symptomatic (pain, fatigue, anxiety about rupture)
• Post-treatment: Generally excellent if cure achieved
• Long-term complications: Recurrence anxiety, need for prolonged follow-up

---

11. Prevention and Public Health

Primary Prevention (Preventing Human Infection)

Control of Definitive Host (Dogs):

• Regular anthelmintic treatment (praziquantel every 6 weeks in endemic areas)
• Control of stray dog populations
• Educate dog owners: Prevent dogs eating infected viscera

Environmental Hygiene:

• Safe disposal of livestock offal (bury deeply or incinerate; do not feed to dogs)
• Hand hygiene after contact with dogs
• Washing vegetables thoroughly

Food Safety:

• Avoid consumption of unwashed wild vegetables in endemic areas
• Safe water supply

Health Education:

• Community education in endemic areas
• Awareness of transmission routes
• Promote early presentation if symptomatic

Secondary Prevention (Preventing Complications)

• Screening in endemic areas (ultrasound surveys)
• Early diagnosis and treatment before complications develop
• Avoid trauma to known cysts

Veterinary Control (Breaking Transmission Cycle)

• Treatment of infected livestock (not feasible in most endemic areas)
• Vaccination of sheep (EG95 vaccine): Highly effective, used in endemic countries [15]
• Abattoir surveillance and safe disposal of infected organs

Global Programs

WHO Echinococcosis Control Programs:

• Integrated approach: Dog treatment, health education, abattoir control, vaccination
• Success in countries like Tasmania, New Zealand, Argentina (regional elimination)

Surveillance:

• Notification of cases (mandatory in some countries)
• Monitoring prevalence in livestock and dogs

---

12. Evidence and Guidelines

Key Guidelines

1. WHO Informal Working Group on Echinococcosis (WHO-IWGE): Expert consensus on diagnosis and treatment of CE and AE (2010, updated 2020) [5,10]

   • Established WHO ultrasound classification (CE1-CE5)
   • Treatment recommendations by cyst stage
   • PAIR protocol standardization

2. Brunetti et al. (2010): Expert consensus for diagnosis and treatment of cystic and alveolar echinococcosis [10]

   • Multi-disciplinary expert panel
   • Evidence-based recommendations

3. WHO Echinococcosis Fact Sheet: Global epidemiology, control strategies

Key Evidence

Albendazole Efficacy:

• Cochrane Review: Albendazole reduces cyst viability and size but cure rates modest (30-40%); best for small cysts [13]
• Optimal duration unclear; prolonged treatment (6+ months) appears superior

PAIR vs Surgery:

• Meta-analyses: PAIR shows comparable efficacy to surgery for suitable cysts (CE1, CE3a), with lower morbidity, shorter hospitalization [14]
• Surgery remains gold standard for complicated cysts, CE2/CE3b

Scolicidal Agents:

• Hypertonic saline (20%) and ethanol (95%) both effective; no clear superiority [7]
• Cetrimide less commonly used

Vaccination (Veterinary):

• EG95 vaccine: > 95% protection in sheep against infection; field trials show dramatic reductions in transmission [15]
• Not available for human use

---

13. Examination Focus

For MRCP/Infectious Diseases Viva

Core Knowledge:

1. Life cycle: Dog-sheep-human triangle, accidental intermediate host
2. Pathognomonic imaging: Daughter cysts, hydatid sand, water-lily sign
3. WHO classification: CE1-CE5, management implications
4. Treatment options: Albendazole, PAIR, surgery - when to use each
5. Key complication: Cyst rupture → anaphylaxis (IgE-mediated)

Classic Viva Scenario:

Examiner: "A 40-year-old shepherd from rural Spain presents with right upper quadrant discomfort. Ultrasound shows a 6 cm cystic lesion in the liver with multiple smaller cysts inside it. What is your differential diagnosis?"

Model Answer: "This imaging description - a cystic lesion containing multiple daughter cysts - is highly suggestive of hydatid disease (cystic echinococcosis). The patient's occupation (shepherd) and origin (endemic area) support this. Differential diagnoses include pyogenic or amoebic liver abscess, simple cyst, or cystic neoplasm, but the daughter cysts are virtually pathognomonic for hydatid disease.

I would confirm the diagnosis with echinococcal serology (IgG ELISA) and classify the cyst using the WHO-IWGE ultrasound classification. The description suggests a CE2 cyst (multivesicular with daughter cysts), which is an active, viable cyst.

Management would involve pre-treatment with albendazole 400 mg twice daily for at least 4 days, followed by either PAIR procedure or surgery depending on local expertise and cyst characteristics. I would ensure anaphylaxis preparedness during the procedure, as cyst rupture or spillage can cause life-threatening anaphylaxis. Post-procedure, I would continue albendazole for 1-3 months to reduce recurrence risk."

Follow-Up Questions:

Q1: "Why is anaphylaxis a risk?"

A1: "Hydatid cyst fluid contains highly antigenic parasitic proteins. Chronic low-level leakage sensitizes the host's immune system with IgE production. Acute rupture or spillage during intervention exposes the host to a massive antigen load, triggering mast cell degranulation and type I hypersensitivity (anaphylaxis). This is why pre-treatment with albendazole to reduce cyst viability, scolicidal agents, and resuscitation preparedness are essential."

Q2: "What is the PAIR procedure?"

A2: "PAIR stands for Puncture-Aspiration-Injection-Reaspiration. It's a minimally invasive ultrasound-guided treatment for selected cysts (CE1 and CE3a, > 5 cm). Under ultrasound guidance, a needle is inserted into the cyst, fluid is aspirated, a scolicidal agent (typically hypertonic saline 20% or 95% ethanol) is injected, left for 15-20 minutes, and then re-aspirated. This sterilizes the cyst. It requires albendazole pre-treatment and post-treatment and is contraindicated for cysts with biliary communication or superficial cysts at high rupture risk. It has cure rates of 70-90% with lower morbidity than surgery."

Q3: "What follow-up would you arrange?"

A3: "I would arrange ultrasound imaging at 6, 12, and 24 months, then annually for 5 years to monitor for cyst regression and detect recurrence. Serology can be used adjunctively; declining titres suggest successful treatment, though antibodies may persist for years. I would educate the patient about rupture symptoms and advise immediate medical attention if severe abdominal pain or allergic symptoms develop."

For Surgery Viva (MRCS/FRCS)

Focus Areas:

1. Surgical anatomy: Hepatic segments, relationship to bile ducts and vessels
2. Intra-operative management: Scolicidal agents, isolation of field, avoiding spillage
3. Biliary fistula management: Recognition (bile in cyst fluid), repair techniques
4. Choice of operation: Cystectomy vs pericystectomy vs resection

Classic Viva Scenario:

Examiner: "You are performing a laparotomy for a large hepatic hydatid cyst. What are your key intra-operative steps to prevent complications?"

Model Answer: "The primary goals are to prevent cyst rupture, spillage, and anaphylaxis. My key steps would be:

1. Pre-operative: Ensure albendazole pre-treatment (at least 4 days), and anaphylaxis preparedness in theatre (adrenaline, resuscitation equipment).

2. Isolation: Pack off the operative field with swabs soaked in scolicidal agent (hypertonic saline 20%) to contain any spillage.

3. Aspiration: Before opening the cyst, aspirate contents percutaneously to reduce intra-cystic pressure and risk of rupture during manipulation. Send aspirate for microscopy (protoscoleces) and culture (secondary infection).

4. Scolicidal injection: Inject hypertonic saline 20% into the cyst and leave for 5-10 minutes to sterilize contents.

5. Cyst opening: Carefully open the cyst and evacuate contents (fluid, membranes, daughter cysts).

6. Inspect for biliary communication: Check for bile in the cyst fluid. Perform methylene blue test if suspected (inject via T-tube or cystic duct and observe for blue dye in cyst cavity). Suture-close any fistulae identified.

7. Cyst management: Perform cystectomy (removal of germinal and laminated layers) or pericystectomy (complete excision including pericyst) depending on cyst size and location. Manage residual cavity with omentoplasty or capitonnage.

8. Drainage: Place drain near the cyst cavity to detect bile leaks post-operatively.

9. Post-operative: Continue albendazole 400 mg BD for 1-3 months, monitor for bile leak, infection, and recurrence."

High-Yield MCQ Topics

1. Life cycle identification (dog = definitive host, human = accidental intermediate)
2. WHO classification (CE1-CE5 and management)
3. Imaging findings (daughter cysts = pathognomonic)
4. Anaphylaxis mechanism (IgE-mediated, cyst fluid antigens)
5. PAIR indications and contraindications
6. Albendazole dosing and side effects (hepatotoxicity monitoring)
7. Scolicidal agents (hypertonic saline vs ethanol)
8. Endemic areas (Mediterranean, Middle East, South America, Central Asia)

---

14. Patient and Layperson Explanation

What is Hydatid Disease?

Hydatid disease is an infection caused by a tiny tapeworm parasite called Echinococcus. This parasite normally lives in the intestines of dogs and some wild animals like foxes. The parasite passes eggs in the dog's faeces, which can contaminate soil, water, and food.

How Do Humans Get Infected?

Humans become infected accidentally by swallowing the parasite eggs, usually through:

• Close contact with infected dogs (eggs on fur, saliva, paws)
• Eating unwashed vegetables or food contaminated with dog faeces
• Drinking contaminated water

It's important to note that you cannot catch hydatid disease from another person - only from dogs or contaminated environments.

What Happens After Infection?

Once swallowed, the eggs hatch in your intestines. The tiny larvae then travel through your bloodstream to organs, most commonly the liver (7 out of 10 cases) or lungs (2 out of 10 cases). There, they form slow-growing fluid-filled cysts. These cysts can take many years (sometimes 10-20 years) to grow large enough to cause symptoms, which is why many people don't even know they're infected until a scan is done for another reason.

What Are the Symptoms?

• Many people have no symptoms for years
• Liver cysts: May cause a dull ache in the upper right part of the abdomen, feeling a lump, or yellowing of the skin (jaundice) if the cyst presses on bile ducts
• Lung cysts: May cause a cough, chest pain, or coughing up blood if the cyst ruptures into the airways

What's Dangerous About Hydatid Cysts?

The main danger is if a cyst ruptures (bursts). The fluid inside contains parasite material that can cause a severe allergic reaction called anaphylaxis, which can be life-threatening. Signs include sudden rash, difficulty breathing, and collapse. If this happens, it's a medical emergency requiring immediate hospital treatment.

How is it Diagnosed?

• Ultrasound or CT scan: Shows the characteristic cyst with smaller "daughter cysts" inside - this appearance is unique to hydatid disease
• Blood test: Checks for antibodies against the parasite

How is it Treated?

Treatment depends on the size, location, and stage of the cyst:

1. Watch-and-Wait: If the cyst is inactive (old, calcified, not growing), we may just monitor it with regular scans.

2. Medication: A drug called albendazole is used to kill the parasite. It's taken as tablets for several months. It works best for smaller cysts.

3. PAIR Procedure: For suitable cysts, a doctor can insert a needle through the skin (using ultrasound guidance), drain the cyst, inject a solution to kill the parasite, and drain it again. This is less invasive than surgery.

4. Surgery: For large cysts or those causing complications, surgery is needed to remove the cyst. This is done carefully to avoid spillage.

What About Side Effects?

• Albendazole: Can affect liver function, so blood tests are done regularly during treatment. Most people tolerate it well.
• PAIR/Surgery: There's a small risk of the cyst rupturing during the procedure, which is why doctors are prepared with emergency equipment.

Will I Fully Recover?

Yes, most people who receive appropriate treatment make a full recovery. Treatment is very effective (85-95% cure rate with surgery, 70-90% with PAIR). Follow-up scans are needed for a few years to make sure the cyst has gone and hasn't come back.

How Can I Prevent It?

• Wash your hands thoroughly after touching dogs, especially in areas where hydatid disease is common
• Wash vegetables and fruits thoroughly before eating
• Avoid contact with stray dogs in endemic areas
• If you own a dog in an endemic area, have it treated regularly by a vet to prevent it carrying the parasite

Is it Common?

It's rare in countries like the UK but common in rural farming areas of the Mediterranean, Middle East, South America, Central Asia, and parts of Australia and Africa. People who work with sheep, goats, and dogs in these areas are at higher risk.

---

15. References

Primary Guidelines and Consensus Statements

1. Jarvis J, Harnett G. Hydatid Disease. StatPearls. 2025. PMID: 40944955.

2. Deplazes P, Rinaldi L, Alvarez Rojas CA, et al. Global Distribution of Alveolar and Cystic Echinococcosis. Adv Parasitol. 2017;95:315-493. doi:10.1016/bs.apar.2016.11.001. PMID: 28131365.

3. Agudelo Higuita NI, Brunetti E, McCloskey C. Cystic Echinococcosis. J Clin Microbiol. 2016;54(3):518-523. doi:10.1128/JCM.02420-15. PMID: 26677245.

4. Lupia T, Corcione S, Angelone L, De Rosa FG. Pulmonary Echinococcosis or Lung Hydatidosis: A Narrative Review. Trop Med Infect Dis. 2021;6(1):12. doi:10.3390/tropicalmed6010012. PMID: 33297827.

5. Brunetti E, Kern P, Vuitton DA; Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010;114(1):1-16. doi:10.1016/j.actatropica.2009.11.001. PMID: 19931502.

6. Brunetti E, Tamarozzi F, Macpherson C, et al. Ultrasound and Cystic Echinococcosis. Ultrasound Int Open. 2018;4(3):E70-E78. doi:10.1055/a-0650-3807. PMID: 30364890.

7. Akhan O, Salik AE, Ciftci T, Akinci D, Islim F, Akpinar B. Percutaneous treatment of liver hydatid cysts: to PAIR or not to PAIR. Diagn Interv Radiol. 2023;29(6):766-776. doi:10.4274/dir.2023.232278. PMID: 37548385.

8. Jensenius M, Amundsen EJ, Capretti MG, et al. Alveolar echinococcosis. Lancet Infect Dis. 2024;24(11):e685-e697. doi:10.1016/S1473-3099(24)00295-7. PMID: 39254012.

9. Woolsey ID, Jensen PM, Deplazes P, et al. Echinococcus granulosus sensu lato and Echinococcus multilocularis: A review. Res Vet Sci. 2021;135:517-522. doi:10.1016/j.rvsc.2020.11.010. PMID: 33246571.

10. Wen H, Vuitton L, Tuxun T, et al. Echinococcosis: Advances in the 21st Century. Clin Microbiol Rev. 2019;32(2):e00075-18. doi:10.1128/CMR.00075-18. PMID: 30760475.

11. Pavlidis ET, Pavlidis TE. Current considerations for the management of liver echinococcosis. World J Hepatol. 2025;17(1):100479. doi:10.4254/wjh.v17.i1.100479. PMID: 40093668.

12. Berto CG, Nardi M, Sarno G, et al. Surgical management of cystic echinococcosis of the liver. Updates Surg. 2023;75(6):1477-1490. doi:10.1007/s13304-023-01600-8. PMID: 37548389.

13. Dehkordi AB, Sanei B, Yousefi M, et al. Albendazole and Treatment of Hydatid Cyst: Review of the Literature. Infect Disord Drug Targets. 2019;19(2):101-104. doi:10.2174/1871526518666180417122314. PMID: 29956639.

14. Kuehn R, Fahrner R, Grat M, de Santibañes E. Treatment of uncomplicated hepatic cystic echinococcosis (hydatid disease). Cochrane Database Syst Rev. 2024;8(8):CD012161. doi:10.1002/14651858.CD012161.pub2. PMID: 38994714.

15. Heath DD, Jensen O, Lightowlers MW. Progress in control of hydatidosis using vaccination--a review of formulation and delivery of the vaccine and recommendations for practical use in control programmes. Acta Trop. 2003;85(2):133-143. doi:10.1016/s0001-706x(02)00219-x. PMID: 12606092.

16. Aziz H, Rather AA, Wani NA, Zargar SA. Cystic echinococcosis of the liver. Ann Med Surg (Lond). 2025;87(2):1208-1214. doi:10.1097/MS9.0000000000002909. PMID: 39864780.

17. Weber TF, Maurer M, Migliorini D, et al. Pulmonary cystic echinococcosis. Lancet. 2023;402(10404):760. doi:10.1016/S0140-6736(23)01270-0. PMID: 37578473.

18. Beacom S, McGinty K, Burdette SD. Isolated pulmonary hydatid cyst. BMJ Case Rep. 2023;16(8):e254944. doi:10.1136/bcr-2023-254944. PMID: 37541696.

---

This topic summary is designed for postgraduate medical trainees preparing for examinations (MRCP, MRCS, FRCS) and clinicians managing parasitic infections in endemic or imported settings. Content is evidence-based and cited from peer-reviewed literature (PubMed indexed). Last updated: 7 January 2026.